Jazz Pharmaceuticals delivers extensive late-breaking data at SLEEP 2026, demonstrating real-world impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on patient outcomes across narcolepsy and idiopathic hypersomnia
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced 11 late-breaking presentations at SLEEP 2026, including notable new research showcasing the comprehensive treatment outcomes of Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution in patients with narcolepsy and idiopathic hypersomnia (IH). These late-breaking presentations advance scientific understanding of individualized dosing regimens and the broader cardiometabolic impacts of reduced sodium exposure in patients living with these debilitating conditions.
“Treating rare sleep conditions like narcolepsy and idiopathic hypersomnia requires a holistic approach that extends beyond immediate symptoms. Because these patients face greater cardiovascular risk, managing sodium intake is a critical component of their care,” said Logan Schneider, M.D., adjunct clinical associate professor of sleep medicine, Stanford Sleep Center and Consultant Neurologist, Stanford/VA Alzheimer’s Center. “These new data from Jazz continue to build on our understanding of the relationship between sleep architecture and patient-reported sleep and improvements in patient-reported daytime symptoms, as well as how sodium reduction directly impacts patient well-being and considerations when personalizing therapy.”
“The breadth and rigor of the evidence we are presenting at SLEEP 2026 reflects years of dedicated scientific inquiry into narcolepsy and idiopathic hypersomnia,” said Jessa Alexander, Ph.D., neuroscience therapeutic area head, global medical and scientific affairs of Jazz Pharmaceuticals. “Jazz is advancing the scientific understanding of these rare sleep conditions with novel data which demonstrates the potential of Xywav’s individualized dosing optimization and the impact of its low-sodium formulation within the context of elevated cardiovascular and cardiometabolic risk. Our research is illuminating the transformative potential of Xywav to deliver outcomes which shape treatment paradigms and have the potential to improve the quality of life for patients living with these conditions.”
Key findings from these late-breaking presentations provide insights into the complex landscape of sleep disorders, across key areas such as:
Xywav Individualized Dosing Supports Personalized Treatment Regimens (P-41, Posters #528 and #529)
New analyses demonstrate that the individualized dosing regimens Xywav allows can be uniquely tailored for patients with narcolepsy or IH. A post-hoc analysis from the Phase 4, prospective, single-arm, open-label DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) study shows how incremental dose adjustments can yield a variety of once- or twice-nightly regimens based on efficacy and tolerability of the individual patient. Within the study cohorts, the mean (range) time to reach a stable dose was 42.1 (14-62) days for idiopathic hypersomnia and 41.8 (12-67) days for narcolepsy. Reinforcing the real-world applicability of this approach, data from the Xywav REMS program, which analyzed over 13,000 patients, demonstrated the feasibility of individualized, patient-centered care enabled by Xywav’s oral solution formulation when clinically warranted.
Xywav is the only low-sodium oxybate approved by the U.S. Food and Drug Administration for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy and for the treatment of IH in adults. The Xywav label recommends a nightly dosage of 6-9 grams per night.
The Impact of a Low-Sodium Formulation Option on Long-Term Cardiometabolic Health (P-41, Posters #526 and #527)
New data showcases that Xywav’s low-sodium formulation extended health benefits beyond the core symptoms of narcolepsy and IH, offering meaningful health gains for patients managing the long-term consequences of these conditions. Secondary results from the open-label, single-arm Phase 4 XYLO study indicate that patients with narcolepsy who switched from high-sodium oxybate to Xywav reported qualitative improvements in symptoms associated with sodium/fluid imbalance, such as edema, diaphoresis, and nocturia, highlighting the clinical benefits of lowering sodium exposure. Moreover, a novel retrospective analysis using electronic health records showed decreases in lipid biomarkers associated with cardiovascular/cardiometabolic (CV/CM) risk, including non-high-density lipoprotein (HDL) cholesterol and triglycerides after Xywav initiation, suggesting risk mitigation for CV/CM outcomes in this patient population. Notably, among the subset of patients with baseline high-sodium oxybate use, initiation of Xywav was associated with additional CM benefits, including a decrease in office-based systolic blood pressure and an increase in HDL cholesterol.
The full abstracts will be available online at: sleepmeeting.org/abstract-supplements
